Acadian Asset Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $42.1M | Sell |
986,764
-508,376
| -34% | -$27.6M | 0.05% | 285 |
|
|
2026
Q1 | $93.8M | Buy |
1,495,140
+413,867
| +38% | +$33.1M | 0.13% | 152 |
|
|
2025
Q4 | $103M | Buy |
1,081,273
+224,967
| +26% | +$22.1M | 0.17% | 119 |
|
|
2025
Q3 | $83.6M | Sell |
856,306
-31,172
| -4% | -$3.23M | 0.15% | 137 |
|
|
2025
Q2 | $95.3M | Buy |
887,478
+281,249
| +46% | +$28.5M | 0.2% | 110 |
|
|
2025
Q1 | $61.1M | Buy |
606,229
+492,891
| +435% | +$49.6M | 0.17% | 122 |
|
|
2024
Q4 | $10.1M | Buy |
113,338
+95,227
| +526% | +$8.38M | 0.03% | 352 |
|
|
2024
Q3 | $1.52M | Sell |
18,111
-23,117
| -56% | -$1.82M | ﹤0.01% | 821 |
|
|
2024
Q2 | $3.17M | Sell |
41,228
-52,030
| -56% | -$3.81M | 0.01% | 631 |
|
|
2024
Q1 | $6.38M | Buy |
93,258
+43,916
| +89% | +$2.82M | 0.02% | 409 |
|
|
2023
Q4 | $2.85M | Buy |
49,342
+22,411
| +83% | +$1.2M | 0.01% | 589 |
|
|
2023
Q3 | $1.42M | Sell |
26,931
-72,673
| -73% | -$3.81M | 0.01% | 776 |
|
|
2023
Q2 | $5.38M | Buy |
99,604
+94,454
| +1,834% | +$4.93M | 0.02% | 440 |
|
|
2023
Q1 | $257K | Buy |
+5,150
| New | +$243K | ﹤0.01% | 1200 |
|
|
2022
Q4 | – | Sell |
-38,878
| Closed | -$1.5M | – | 1780 |
|
|
2022
Q3 | $1.5M | Sell |
38,878
-136,686
| -78% | -$5.48M | 0.01% | 703 |
|
|
2022
Q2 | $6.54M | Buy |
175,564
+174,767
| +21,928% | +$7.11M | 0.03% | 353 |
|
|
2022
Q1 | $35K | Buy |
+797
| New | +$34.5K | ﹤0.01% | 1504 |
|
|
2021
Q4 | – | Sell |
-15,163
| Closed | -$656K | – | 1682 |
|
|
2021
Q3 | $656K | Sell |
15,163
-2,208
| -13% | -$97.7K | ﹤0.01% | 969 |
|
|
2021
Q2 | $743K | Buy |
17,371
+12,515
| +258% | +$527K | ﹤0.01% | 1021 |
|
|
2021
Q1 | $187K | Sell |
4,856
-9,761
| -67% | -$369K | ﹤0.01% | 1521 |
|
|
2020
Q4 | $525K | Sell |
14,617
-6,372
| -30% | -$230K | ﹤0.01% | 1220 |
|
|
2020
Q3 | $802K | Buy |
20,989
+13,199
| +169% | +$509K | ﹤0.01% | 984 |
|
|
2020
Q2 | $274K | Hold |
7,790
| – | – | ﹤0.01% | 1385 |
|
|
2020
Q1 | $254K | Buy |
7,790
+3,346
| +75% | +$131K | ﹤0.01% | 1142 |
|
|
2019
Q4 | $201K | Buy |
+4,444
| New | +$186K | ﹤0.01% | 1291 |
|
|
2019
Q2 | – | Sell |
-2,569
| Closed | -$99K | – | 1830 |
|
|
2019
Q1 | $99K | Sell |
2,569
-3,639
| -59% | -$139K | ﹤0.01% | 1520 |
|
|
2018
Q4 | $219K | Sell |
6,208
-7,062
| -53% | -$256K | ﹤0.01% | 1094 |
|
|
2018
Q3 | $511K | Buy |
13,270
+6,911
| +109% | +$241K | ﹤0.01% | 874 |
|
|
2018
Q2 | $208K | Buy |
+6,359
| New | +$192K | ﹤0.01% | 1074 |
|
Other funds holding BSX
VCM
VPM
Acadian Asset Management's BSX Position: Q2 2026 in Review
Acadian Asset Management reduced its Boston Scientific (BSX) stake by 34% in Q2 2026, selling an estimated $27.6M and leaving 986,764 shares worth $42.1M. The position accounts for 0.05% of the portfolio, ranked #285.
Acadian Asset Management first reported a position in BSX in Q2 2018 and has held it in 29 quarters since. The position peaked at $103M in Q4 2025. 1,176 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Acadian Asset Management held 986,764 shares of Boston Scientific worth $42.1M as of Q2 2026.
- Acadian Asset Management sold 508,376 Boston Scientific shares in Q2 2026, an estimated $27.6M.
- Boston Scientific made up 0.05% of Acadian Asset Management's portfolio in Q2 2026, its #285 holding.
- Acadian Asset Management first reported a position in Boston Scientific in Q2 2018 and has held it in 29 quarters since.
- Acadian Asset Management's Boston Scientific position peaked at $103M in Q4 2025.
- 1,176 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.